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Abstract The development of obesity is becoming an
international problem and the role of fructose is unclear.
Studies using liver tissue and hepatocytes have contributed to
the understanding of fructose metabolism. Excess fructose
consumption also affects extra hepatic tissues including adi-
pose tissue. The effects of fructose on human adipocytes are
not yet fully characterized, although in vivo studies have
noted increased adiposity and weight gain in response to
fructose sweetened-beverages. In order to understand and
predict the metabolic responses of adipocytes to fructose, this
study examined differentiating and differentiated human
adipocytes in culture, exposed to a range of fructose con-
centrations equivalent to that reported in blood after con-
suming fructose. A stable isotope based dynamic profiling
method using [U-13C6]-D-fructose tracer was used to examine
the metabolism and fate of fructose. A targeted stable isotope
tracer fate association method was used to analyze metabolic
fluxes and flux surrogateswith exposure to escalating fructose
concentration. This study demonstrated that fructose stimu-
lates anabolic processes in adipocytes robustly, including
glutamate and de novo fatty acid synthesis. Furthermore,
fructose also augments the release of free palmitate from fully
differentiated adipocytes. These results imply that in the
presence of fructose, the metabolic response of adipocytes in
culture is altered in a dose dependent manner, particularly
favoring increased glutamate and fatty acid synthesis and
release, warranting further in vivo studies.
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Increased and frequent consumption of diets rich in sucrose
(table sugar) and/or high fructose corn syrup (sweetener
used in confectionaries and many beverages) expose the
body to high levels of glucose and fructose. The con-
sumption of sugar and sweeteners has increased for the past
40 years and is thought to be associated with the devel-
opment of obesity, type II diabetes and cardiovascular
diseases (Bray 2004; Brown 2008; Goran et al. 2013;
Johnson et al. 2007; Kmietowicz 2012; Sheludiakova et al.
2012). Much attention has been focused on fructose based
on its reported effects of increasing circulating triglycer-
ides, dyslipidemia, hyperuricemia, and obesity (Lustig
2010; Tappy and Le 2010). Unlike glucose, fructose is not
universally metabolized by all tissues of the body and is not
a necessary nutrient for the body. Fructose is primarily and
efficiently metabolized by the liver as demonstrated by
in vivo and in vitro studies (Elliott et al. 2002; Lim et al.
2010; Mayes 1993; Neuschwander-Tetri 2013). Only
insignificant amounts of fructose enter the systemic circu-
lation on consumption of a normal healthy diet. However,
the frequent and high consumption of sugar-based bever-
ages and food is reported to causes dyslipidemia, non-
alcoholic fatty liver diseases, and other metabolic disorders
(Kavanagh et al. 2013; Samuel 2011). High circulating
levels of fructose overwhelms the ability of the liver to
metabolize the ingested fructose completely, resulting in a
spillover of fructose into the systemic circulation (Hui
et al. 2009; Munstedt et al. 2011). Excess fructose in the
blood is subsequently cleared through the kidneys or it is
taken up and metabolized by extra-hepatic tissues, notably
adipose, where it may contribute to the development of
obesity.
Adipose tissue is a highly active metabolic and endo-
crine-producing organ (Kershaw and Flier 2004). The
metabolic state of the adipose tissue is altered in a dynamic
manner in response to the nutritional state by varying and
modifying the substances that are taken up or released
from it (Frayn et al. 2003; Tan and Vidal-Puig 2008).
White adipose tissue can act as a sink of excess energy due
to its ability to regulate its own metabolism, either by
controlling the differentiation of adipocytes and/or by
inducing tissue expansion under conditions of positive
energy balance occurring in nutritionally rich states (Frayn
et al. 2003). Accumulation and storage of triglycerides can
promote the development of obesity. Excess adipose tissue
can contribute to increased release of free fatty acids
(FFA) into circulation. FFA can deposit ectopically in
organs such as skeletal muscle, liver, pancreas and car-
diovascular tissue resulting in lipotoxicity and insulin
resistance (Axelsen et al. 2010; Snel et al. 2012; Tan and
Vidal-Puig 2008).
Fructose metabolism in extra-hepatic tissues is not well
studied. Increased fructose levels in the circulation may
alter the metabolic characteristics and the function of tis-
sues that metabolize fructose, particularly adipose. Some
studies have demonstrated increases in visceral adipose
tissue (VAT) volumes and weight gain on exposure to
fructose-containing beverages both in human and rodent
models (Elliott et al. 2002; Lim et al. 2010; Mayes 1993;
Neuschwander-Tetri 2013; Pollock et al. 2012; Ronn et al.
2012). A few earlier studies have examined the metabolism
of fructose in rat adipose tissue and some of these studies
focused on adipose tissue as a site of extra hepatic fructose
metabolism in the presence of hereditary fructose intoler-
ance (Bellido and Herrera 1978; Froesch and Ginsberg
1962). There are no studies to our knowledge that have
examined the metabolism and fate of fructose in human
adipocytes. Hence, the goal of this study was to charac-
terize the metabolic responses of adipocytes to fructose and
to better understand the fate of fructose in adipocytes.
Human Simpson-Golabi-Behmel Syndrome (SGBS)
adipocytes (Wabitsch et al. 2001) were used in this study
because of its similarities to isolated human adipocytes. To
perform this study, a stable isotope based dynamic profiling
(SIDMAP) method (Singh et al. 2013) with uniformly
labeled fructose [U-13C6]-D-fructose was used to examine
the metabolism and fate of fructose in these adipocytes.
The process of adipocyte differentiation is known to entail
changes in the metabolite concentrations and alteration of
specific pathways including tricarboxylic acid (TCA)
cycle, glycolysis, and fatty acid synthesis, between differ-
entiating and differentiated adipocytes (Roberts et al.
2009). Hence, this study examined the responses of adi-
pocytes to fructose at two different time points during
adipocyte differentiation including day 8 when adipocytes
are predominantly in the differentiating state and at day 16
when the adipocytes were fully differentiated. Based on
most common dietary fructose exposures, a broad range of
fructose concentrations was examined to predict the met-
abolic responses of adipocytes to fructose. Additionally, a
targeted stable isotope tracer fate association method
(Singh et al. 2013) was used to analyze metabolic fluxes
using flux surrogates.
2 Materials and methods
2.1 Chemicals and reagents
Dexamethasone, 3-isobutyl-1-methylxanthine (IBMX),
transferrin, cortisol, triiodothyronine (T3), biotin, panto-
thenate, dichloromethane, trifluoroacetic anhydride, etha-
nol, potassium hydroxide (KOH), sodium bicarbonate
(NaHCO3), HCL, acetone, Dulbecco’s Modified Eagle
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Medium (DMEM) powder media, Hams’s F12 powder
media, fructose and glucose were all obtained from
SIGMA Chemical Company (St. Louis, MO, USA). Fetal
bovine serum was obtained from Thermo Fisher Scientific
(Waltham, MA, USA). Rosiglitazone was obtained from
Cayman Chemicals (Ann Arbor, MI, USA), Insulin was
obtained from Novo Nordisk [U-13C6]-D-fructose ([99 %
purity, and 99 % isotope enrichment for all carbons) was
obtained from Cambridge Isotope Laboratories (Andover,
MA, USA), methane and helium ([99.99 % purity), was
obtained from PaxAir (Los Angeles, CA, USA), and n-
butanol was obtained from Regis Chemical. Company
(Chicago, IL, USA).
2.2 SGBS cell culture
Human SGBS preadipocytes, that have been described
previously (Wabitsch et al. 2001) were kindly provided by
Martin Wabitch and used in this study. In brief, the SGBS
preadipocytes cells were maintained at 37 C in a humid-
ified incubator containing a 5 % O2 atmosphere. The
growth medium consisted of DMEM:F12 (1:1), 33 mM
biotin, and 17 mM pantothenate containing 10 % fetal
bovine serum and 1 % penicillin–streptomycin. One day
post-confluence, the cells were initiated to differentiate into
adipocytes by addition of a serum-free differentiation
medium containing DMEM with 25 nM dexamethasone,
500 lM IBMX, 2 lM rosiglitazone, 0.01 mg/ml human
transferrin, 2 9 10-8 M insulin, 10-7 M cortisol, 0.2 nM
T3, 33 mM biotin, and 17 mM pantothenate. The cells
were maintained in differentiation medium for 4 days after
which the medium was changed to a serum-free adipogenic
medium consisting of DMEM:F12 (1:1) with 0.01 mg/ml
human transferrin, 2 9 10-8 M insulin, 10-7 M cortisol,
0.2 nM T3, 33 mM biotin, and 17 mM pantothenate).
Adipogenic medium is essentially similar to the differen-
tiation medium but lacks IBMX, dexamethasone and ros-
iglitazone. Medium was changed every 2 days from the
initiation of differentiation. Cells were allowed to differ-
entiate and harvested after 8 or 16 days. SGBS cells
completely differentiate into adipocytes by day 14 of
differentiation.
2.3 Fructose treatment of SGBS cells and labeling
using U 13C6-D-fructose tracer
SGBS preadipocytes were plated at 2 9 105 cells in
60 mm dishes supplemented with 3 ml growth medium
(described above) and grown to confluence. All media used
for the growth, differentiation and maintenance of adipo-
cytes contained a basal amount of 5 mM glucose, equiva-
lent to the normal blood glucose concentration. In order to
determine the effects of fructose exposure to adipocytes at
concentrations reported in the systemic circulation fol-
lowing exposure to fructose-rich food (Hui et al. 2009),
0.1, 0.5, 1.0, 2.5, 5, 7.5, 10 mM fructose was added to the
media at the initiation of differentiation and maintained in
the medium until the collection of cells and medium at end
points of either day 8 or until day 16 of differentiation. In
order to trace the metabolism of fructose in adipocytes, and
to understand the major flow and fate of fructose derived
carbons in human adipocytes, a labeled fructose tracer
([U-13C6]-D-fructose) was utilized. In this experimental
paradigm, the labeled fructose was used at 10 % of the
respective fructose concentrations. Under such conditions
the 13C fructose becomes the single tracer of intermediary
metabolism by its positional 13C carbon contributions to
metabolic products. The tracer was added to cells on day 6
and day 14 respectively for a period of 48 h to enable
sampling at two different time points, day 8 and day 16
after 48 h. Cell lysates and media were collected for met-
abolomic assays at endpoints of day 8 and 16. Each con-
centration was tested in triplicate cultures. For each
replicate, samples from two confluent 60 mM dishes were
pooled during collection to ensure sufficient material for all
assays. At the time of collection, 6 ml of media was first
collected centrifuged at 7519g for 10 min to remove any
dead or floating cells and flash frozen. The cells were
rinsed twice with cold PBS and aspirated to remove any
remaining medium. 300 ll portion of cold PBS was added
to each 60 mm dish, and the cells were scraped and col-
lected, flash frozen and stored at -80 C until used. Tracer
labeled endpoints such as extracellular CO2, intra- and
extra-cellular glutamine, intra- and extra-cellular fatty
acids including palmitate and oleate, lactate, glycogen and
ribose, some of which are positionally labeled, were
examined as described in the ‘‘Materials and methods’’ and
the ‘‘Results’’ sections presented below.
2.4 Targeted 13C metabolite studies and metabolic
profiling using U 13C6-D-fructose tracer
Specific extractions were performed as described below
and mass spectral data were obtained using a HP5975 N
(Agilent, Palo Alto, CA, USA) mass selective detector
connected to an HP6890N (Agilent, Palo Alto, CA, USA)
gas chromatograph. An Agilent J&W HP-5MS (30 m 9
0.25 mm 9 0.25 lm; part #: 19091S-433) analytical col-
umn was used during glucose, ribose, glutamate, and lac-
tate analyses. For analysis of fatty acids and CO2, an
Agilent J&W Scientific DB-23 (60 m 9 0.25 mm 9
0.15 lm; part #: 122-2361) column was used. Helium
([99.99 % purity) was used as the carrier gas in the elec-
tron impact ionization (EI) mode and methane ([99.99 %
purity, PaxAir, Los Angeles, CA, USA) in the chemical
ionization mode. Sample injections were performed using
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100 split ratios directly into the heated (250 C) and
pressurized inlet interfaces. Results of mass isotopomers in
glutamate are reported as molar fractions where m1, m2,
etc. indicate the number of 13C atoms in the molecule (Lee
et al. 1991). The enrichment, Rmn, is the weighted sum
of the labeled species (Rmn = m1 X 1 ? m2 X 2 ?
m3 X 3…) (Marin et al. 2004; Vizan et al. 2005). Lactate
was extracted from cell culture media (0.2 ml) by ethylene
chloride after acidification with HCl, derivatized to its
propylamine–heptafluorobutyrate ester form and applied to
the column (Lee et al. 1998). Enrichment of 13C-labeled
acetyl units derived from [U-13C6]-fructose in palmitate
and oleate reflect de novo fatty acid synthesis, elongation,
and desaturation, as determined by mass isotopomer dis-
tribution analysis (MIDA) (Hellerstein and Neese 1992;
Lee et al. 1998). Natural 13C abundance of the target and
derivatizing compounds are routinely extracted for MIDA
calculations (Lee 1996). For analysis of fatty acid synthe-
sis, palmitate, and oleate from media or cell pellets were
saponified with 30 % KOH and 100 % ethanol and
extracted using petroleum ether. Fatty acids were converted
to their methylated derivative using 0.5 N HCl in methanol
and methyl palmitate and methyl oleate, dried, reconsti-
tuted in hexane and injected into the GC–MS and moni-
tored at m/z 270, and m/z 264, respectively. Analyses of
complete oxidation of [U-13C6]-fructose to
13CO2, were
performed using 100 ll media samples in GC vials. To
each sample was added 50 ll of 0.1 M NaHCO3 followed
by 50 ll of 1.0 M HCl. The vials were immediately capped
and placed on the GC/MS sample tray for analysis of the m/
z 44 and m/z 45 ion group (Mizumori et al. 2006). Only 13C
labeled product fractions, after their parent ion concentra-
tions are resolved via standard Chemstation Integrator
diagnostics following background subtraction, are reported.
The internal standard is the 13C labeled fructose and its
products as it gets metabolized following its addition at the
time points of days 6 and 14 in adipocytes for a period of
48 h as described above. Glutamate was extracted from
100 ll media using 100 ll ultrapure water and 100 ll
HPLC grade acetone. The mixture was frozen at -80 C
for 1 h, vortexed for 60 s and centrifuged at 13,0009g for
30 min. The supernatant was transferred into a 13 in. glass
test tube on ice and dried under nitrogen. Glutamate was
converted to its N-trifluoroacetyl-n-butyl (TAB) derivative
in two steps (Leimer et al. 1977). Samples were mixed
with 200 ll 3.0 M HCl in n-butanol and incubated at
100 C for 1 h to form butyl esters. Samples were treated
next with 100 ll dichloromethane and 25 ll trifluoroacetic
anhydride at room temperature for 20 min to form TAB-
glutamate and the products were dried under nitrogen. The
residues were transferred into GC vials in 200 ll dichlo-
romethane. When [U-13C6]-fructose is processed by gly-
colysis followed by pyruvate dehydrogenase (PDH), the
[1,2-13C2]-acetyl-CoA produced is used to form [4,5-
13C2]-
glutamate. Alternatively, [3-13C1]-glutamate is produced
from [U-13C6]-fructose when it is processed via the pyru-
vate carboxylase (PC) pathway which leads to [3-13C1]-
oxaloacetate. Under EI conditions, ionization of TAB-
glutamate produces two groups of fragments, m/
z 198 ? 202 and m/z 152 ? 155, corresponding to the
C2–C5 and C2–C4 fragments of glutamate (Bartnik et al.
2007). Therefore, detection of the 13C label on C4 and C5
of the m/z 200 M?2 glutamate fragment ion reflects PDH
activity and hence oxidative phosphorylation (catabolic use
of fructose). PC yields new (net) oxaloacetate for the cycle
from fructose, which forms the anabolic (anaplerotic)
substrate for the cycle. [1,2-13C2]-acetyl-CoA enrichment
is calculated based on palmitate M?4/M?2 ratios as
described previously (Lee et al. 1998). Flux surrogates are
used throughout data interpretations, instead of flux cal-
culations, whereby not (only) metabolite concentrations but
their turnover rates are depicted by specific (positional) 13C
labeling and their associations with fructose dosing. Fig-
ure 1 represents the potential 13C (red squares) labeled
intermediates of lactate and glutamate that are formed from
U13C6-D-glucose and described further in the ‘‘Results’’
section.
2.5 Quantitative metabolite analysis
Media and cell pellet metabolic products were quantified
and compared by integrated peak area values under cor-
responding total ion current (TIC) ID logs as determined by
retention times in the selected ion monitoring mode by
blinded spectra processing personnel (see Acknowledg-
ments section). Average peak width values were less than
5 s (ChemStation Integrator, Agilent, Palo Alto, CA, USA)
using identical injection volume, solvent strength and split
ratios with that of natural 13C-labeled external chromato-
graphic standards. Concentration-dependent integrated
chromatographic TIC areas are displayed as arbitrary val-
ues of metabolite concentration among the control and
fructose treated groups.
2.6 Statistical analysis
Data are presented as arithmetic mean (average) plus
standard error (SEM) of three independent observations
using three independent integration results with back-
ground subtraction of the natural labeled 13C standard and
its derivatizing agent. ANOVA with Dunnett’s test was
used and p B 0.05 was considered to indicate statistically
significant differences in metabolite flux results in response
to fructose treatments of adipocytes. Since this study
examined fructose metabolism using a fructose tracer, the
control used in this study comprised of cells treated with a
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very low concentration of 0.1 mM fructose. A linear
regression analysis with R2 (coefficient of determination)
measurement was performed to describe the relationship
between the fructose dosing and the SGBS adipocyte iso-
topomers measured. Correlation analysis was used to
determine the strength of this association, and a
p value B 0.05 was used to indicate that the correlation is
of statistical significance and different from 0.
3 Results
3.1 Fully differentiated adipocytes showed
only a marginal increase in the oxidation
of fructose
In an in vitro system, extracellular release of [13C]-HCO3 can
be used to evaluate complete oxidation of [U-13C6]-fructose
to CO2 via the TCA cycle following release of
13CO2 from
[13C]-HCO3 using acid and alkali treatments. A measure of
the 13CO2/
12CO2 ratios (replacement of
12C by 13C)
represents the change in 13C labeled extracellular CO2
released into the medium following treatment of cells with
13C labeled monosaccharide and reflects the complete oxi-
dation of themonosaccharide through the TCAcycle.A slight
but significant increase in released CO2, was observed in both
differentiating (Fig. 2a) and differentiated adipocytes
(Fig. 2b) at higher concentrations of fructose compared to the
0.1 mM fructose treatment. These results demonstrated that
adipocytes take up fructose and metabolize it in the TCA
cycle. However, this response is only marginally higher than
the control and a robust dose-dependent response was not
observed in adipocytes with increasing concentrations of
fructose especially in differentiated adipocytes. This suggests
that fructose does not serve as a robust substrate for energy
production by complete oxidation and ATP synthesis. Com-
pared to the differentiating adipocytes (Fig. 2a), the differ-
entiated adipocytes (Fig. 2b) showed an overall higher level
of extracellular CO2 release reflecting more complete oxi-
dation of fructose in the differentiated adipocytes compared to
differentiating adipocytes.
Fig. 1 Representation of potential 13C labeled lactate and glutamate
isotopomers derived from U13C6-D-fructose used as the single tracer.
The red squares represent the 13C labeled carbons in the isotopomers
formed. [2,3 13C2] lactate is derived via the pentose phosphate
pathway (PPP) while the [1,2,3 13C3] lactate is formed via breakdown
of U13C6-D-fructose via glycolysis. [3,
13C1] glutamate and the [2, 3
13C2] glutamate are formed from oxaloacetate which is derived from
pyruvate via the PC flux. [4,5 13C2] glutamate is formed from acetyl-
CoA which is derived from pyruvate via the PDH flux. [2,3,4,5 13C4]
glutamate is formed from recycled 13C labeled carbon entry into TCA
cycle via anaplerosis (Color figure online)
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3.2 Fructose increased extracellular glutamate
indicating an increased anabolic function
Glutamate derived from the TCA cycle intermediate a-
ketoglutarate provides a strategic byproduct for amino acid
biosynthesis. When adipocytes were incubated with fruc-
tose, as described in the ‘‘Materials and methods’’ section,
a significant increase in extracellular [13C]-glutamate was
detected in cultures of both differentiating and fully dif-
ferentiated adipocytes (Fig. 2c, d). The response was sig-
nificant at fructose concentrations of C2.5 mM in
differentiating (Fig. 2c) and in differentiated adipocytes
(Fig. 2d). While the differentiating adipocytes only dem-
onstrate a minor but significant increase in extracellular
glutamate production, the response is very robust in dif-
ferentiated adipocytes, with the 5 mM fructose treatment
dose saturating and exhausting this flux with a sevenfold
increase in [13C]-glutamate. Further increases in fructose
concentration did not additionally augment the conversion
of fructose to glutamate. These results also demonstrated
the distinction between differentiating and differentiated
adipocytes with respect to glutamate production. The
increase in [13C]-glutamate produced from labeled fructose
in differentiated adipocytes suggests a more prominent
anabolic function in mature adipocytes.
3.3 Fructose increased the PDH flux but decreased PC
flux in adipocytes
Carbohydrates, including fructose, undergo glycolysis to
form pyruvate as a metabolic intermediate. Pyruvate enters
into the TCA cycle for anabolic processes or for energy
production (catabolic process). It does so in one of two
ways—either by conversion to acetyl-CoA via the PDH
reaction, the catabolic pathway or by conversion to oxa-
loacetate via the PC reaction, to support gluconeogenesis,
fatty acid synthesis and other anabolic processes. Using
[U-13C6]-fructose enabled analysis of PDH or PC flux by
measuring the glutamate isotopomers that are specific for
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Fig. 2 Fructose oxidation and fructose-derived glutamate synthesis
via TCA cycle. Adipocytes were exposed to 0.1, 0.5, 1, 2.5, 5, 7.5 or
10 mM fructose in a medium containing a baseline amount of 5 mM
glucose from the initiation of differentiation for 8 days (differenti-
ating adipocytes) or 16 days (differentiated adipocytes). 10 % of
fructose was supplied as [U-13C6]-fructose for a period of 48 h before
harvest. Fructose oxidation was measured in differentiating
adipocytes (a) and differentiated adipocytes (b) by the change D in
the 13CO2 released in the extracellular medium measured as a ratio of
13C/12C (replacement of 12C by 13C) in extracellular bi-carbonate. 13C
D is a measure of the ratio of stable isotopes 13C:12C, reported in parts
per thousand (per mil, %). Extracellular release of [13C]-glutamate in
differentiating adipocytes (c) and differentiated adipocytes (d) is
expressed as a percentage of total glutamate released
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The C2–C5 m/z 200 M?2 glutamate fragment ion was
used to measure PDH flux. The amount of [4,5-13C2]-glu-
tamate formed from [U-13C6]-fructose is indicative of the
PDH flux. C2–C5 M?2 labeled glutamate showed a robust
dose-dependent increase in response to fructose in both
differentiating (Fig. 3a) and differentiated adipocytes
(Fig. 3b). The effect was more pronounced in the differ-
entiated adipocytes in terms of magnitude of response and
increased sensitivity in terms of dose. An increase in the
PDH flux suggests that citrate was the primary product
resulting from the entry of fructose into the TCA cycle.
[3-13C1]-glutamate is formed from [U-
13C6]-fructose
when the fructose-derived pyruvate intermediate is pro-
cessed via the PC pathway and this was measured as C2–C5
m/z 199 M?1 glutamate fragment ion. A dose-dependent
decrease in PC flux was observed in both differentiating
(Fig. 3c) and differentiated adipocytes (Fig. 3d) in response
to increasing fructose concentrations. Differentiated cells
had a greater responsiveness compared to differentiating
cells, similar to the PDH flux results. For example, exposure
to 5 mM fructose showed a 1.4-fold decrease in the differ-
entiating adipocytes while this decrease is 3-fold in the
differentiated adipocytes. The decreases in PC flux further
corroborates that fructose-derived pyruvate predominantly
yields citrate via PDH.
3.4 Fructose is not a source of TCA cycle anaplerosis
in differentiating and differentiated adipocytes
Anaplerotic reactions, which are anabolic reactions that
replenish the TCA cycle intermediates, occur constantly for
efficient energy production and new citrate synthesis in the
TCA cycle. Adipocytes exposed to increasing concentra-
tions of fructose demonstrated a dose dependent decrease
in the 13C M?4 glutamate.
13C M?4 glutamate is formed
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Fig. 3 Entry of pyruvate into TCA cycle via PC or PDH flux and
TCA cycle anaplerosis. Adipocytes were exposed to 0.1, 0.5, 1, 2.5, 5,
7.5 or 10 mM fructose in a medium containing a baseline amount of
5 mM glucose from the initiation of differentiation for 8 days
(differentiating adipocytes) or 16 days (differentiated adipocytes).
10 % of fructose was supplied as [U-13C6]-fructose for a period of
48 h before harvest. PC flux was measured in differentiating (a) and
differentiated (b) adipocytes as extracellular [3-13C1] glutamate using
the M?1 RmC2–C5 fragment (one
13C substitution, m/z 199 fragment,
EI) of its 13C labeled fraction. PDH flux was measured in
differentiating (c) and differentiated (d) adipocytes as extracellular
[4,5-13C2] glutamate using M?2 RmC2–C5 fragment (two substitu-
tions, m/z 200 fragment, EI) of its 13C labeled fraction. TCA cycle
anaplerosis was examined in differentiating (e) and differentiated
(f) by measuring the M?4 glutamate flux (M?4 RmC2–C5) (four
13C
substitution, m/z 202 fragment, EI). *p\ 0.05 compared to the
0.1 mM fructose labeled. Please note that the first (C1) carbon of
glutamate is excluded from EI analyses as this carbon may go through
extensive exchange reactions
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newly labeled citrate. A key point is that PC derived
oxaloacetate accepts tracer labeled acetyl-CoA obtained
from fructose derived pyruvate via PDH which then forms
glutamate in the TCA cycle. The 13C M?4 glutamate thus
measures the anabolic use of fructose-derived pyruvate for
oxaloacetate production and its condensation with fructose
derived acetyl-CoA for the production of citrate. In dif-
ferentiated adipocytes (Fig. 3f), 2.5 mM fructose maxi-
mally decreased TCA cycle anaplerosis with no further
decrease in the formation of 13C M?4 glutamate at higher
concentrations of fructose. The 13C M?4 glutamate was
small and accounted for less than 10 % of the total 13C
glutamate that is formed from fructose. Differentiating
adipocytes (Fig. 3e) appeared to be less sensitive to fruc-
tose compared to the fully differentiated adipocytes
(Fig. 3f). A decrease in 13C M?4 glutamate level supports
previous observations that fructose was not an efficient
substrate for maintaining energy production in the cycle.
Previous 13C tracer studies with glucose (Liu et al. 2010)
suggest that the glucose-derived pyruvate pool maintains
TCA cycle anaplerosis in the presence of fructose.
3.5 Fructose robustly increased intracellular palmitate,
de novo palmitate synthesis and the release
of palmitate from adipocytes
Fructose-derived pyruvate enters the TCA cycle via the
PDH flux or PC flux. Entry through the PDH flux results in
the formation of acetyl-CoA that combines with oxaloac-
etate to form citrate. When excess citrate is formed, it can
be shuttled out of the mitochondria and metabolized to
form acetyl-CoA. In combination with malonyl-CoA,
acetyl-CoA acts as a substrate for anabolic reactions of the
lipogenesis pathway leading to the synthesis of fatty acids
such as palmitate (C16:0). We found a statistically signif-
icant increase in intracellular [13C]-palmitate formed in
differentiating (Fig. 4a) and differentiated adipocytes
(Fig. 4b) exposed to increased levels of fructose. The
increase in labeled palmitate was more pronounced in the
differentiated adipocytes (Fig. 4b). These results demon-
strated that fructose was robustly converted to palmitate in
adipocytes and was therefore a potent lipogenic substrate in
this cell type. The result was consistent with increasing
mobilization of fructose towards fatty acid synthesis.
Newly synthesized palmitate contributed only about 5 % of
the total fatty acids at 0.1 mM fructose in both the differ-
entiating (Fig. 4c) and fully differentiated adipocytes
(Fig. 4d). A dose dependent increase in the newly syn-
thesized palmitate occurred in adipocytes cultured in the
presence of 5 mM or higher fructose (Fig. 4c, d). This
response was more robust in differentiated adipocytes
(Fig. 4d) which exhibited a two to ninefold increase in
newly synthesized palmitate between 2.5 and 10 mM,
supporting the conclusion that high concentrations of
fructose increased lipogenesis.
Increasing concentrations of fructose did not signifi-
cantly alter the release of palmitate compared to control in
differentiating adipocytes (Fig. 4e). On the contrary,
simultaneous with the increase in newly synthesized and
labeled intracellular palmitate, differentiated adipocytes
showed a dose-dependent increase in the release of pal-
mitate to the extracellular medium (Fig. 4f). A 1.5–2.0-fold
increase in the release of labeled palmitate from fully
differentiated adipocytes was observed in cells treated with
2.5–10 mM fructose as compared to the 0.1 mM fructose
treated group (i.e., the control). Overall, fructose increased
intracellular palmitate formation in a robust manner in fully
differentiated adipocytes while simultaneously also
increasing the release of palmitate from the cells.
3.6 Fructose increased intracellular oleate
without altering the release oleate
to the extracellular medium
In addition to the increased intracellular synthesis of pal-
mitate and its release, fructose-treated adipocytes also
demonstrated an increase in the accumulation of intracel-
lular oleate in differentiating (Fig. 5a) and differentiated
(Fig. 5b) adipocytes. Oleate is formed by the elongation
and desaturation of palmitate. These results imply that in
addition to the activity of fatty acid synthase, fructose also
increases the action of fatty acid elongase and fatty acid
desaturase to bring about the conversion of palmitate to
oleate thus promoting the storage of fatty acids as both
oleate and palmitate. Oleate synthesis was distinctly higher
in the differentiated adipocytes (Fig. 5b) compared to the
differentiating adipocytes (Fig. 5a). No change was
observed in the release of oleate into the medium in
response to fructose treatment (data not shown).
3.7 Fructose augmented acetyl-CoA formation
and lactate release in adipocytes
Acetyl-CoA is the precursor for the synthesis of fatty acids
including palmitate, and oleate. Fructose augmented the
formation of [1,2-13C2]-acetyl-CoA from labeled fructose
in both differentiating (Fig. 5c) and differentiated (Fig. 5d)
adipocytes. About 15 % of the total pool of acetyl-CoA
was comprised of tracer-labeled [1,2-13C2]-acetyl-CoA in
the 0.1 mM fructose-treated adipocytes group. There was a
dose-dependent increase in the tracer-labeled acetyl-CoA
formed to 35–40 % in both differentiating (Fig. 5c) and
differentiated (Fig. 5d) adipocytes. In adipocytes the
acetyl-CoA pool was formed from the tracer labeled sub-
strate at the expense of fatty acid breakdown via b-oxida-
tion. The results also showed that isotopic enrichment of
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[1,2-13C2]-acetyl-CoA from labeled fructose was aug-
mented in both differentiating and differentiated adipocytes
and are evenly distributed in both. This indicates that
increasing concentrations of fructose yield comparable
acetyl-CoA in both differentiating and differentiated adi-
pocytes. However, the acetyl-CoA formed may be utilized
more in the differentiated adipocytes towards fatty acid
synthesis since fatty acid formation was greater in the
differentiated adipocytes compared to differentiating adi-
pocytes (Fig. 4c, d).
Pyruvate enters into the TCA cycle under aerobic con-
ditions to generate ATP via substrate-level and oxidative
phosphorylation. Under anaerobic conditions, however,
pyruvate can be converted to lactate which also results in
energy production but at a much lower level. Examining
the [13C]-lactate in the extracellular medium revealed that
fully differentiated adipocytes but not differentiating adi-
pocytes, showed show a dose-dependent release of lactate
into the extracellular medium (Fig. 4e, f). The release was
robust only at the higher concentrations of fructose (5, 7.5
and 10 mM) in differentiated adipocytes, suggesting that
adipocytes efficiently produced lactate only in the presence
of excess fructose.
Other potential metabolic endpoints for labeled fructose
include the conversion to glycogen or ribose. In this study,
fructose did not label ribose or glycogen efficiently (data
not shown). This is consistent with the irreversible di-
phosphorylation of fructose-6-phosphate which prevents its
isomerization to glucose-6-phosphate and consequent
metabolism towards glycogen and ribose in the pentose
phosphate pathway.
3.8 Fructose dose correlated significantly
with the SGBS adipocyte isobolome (SGBS
adipocyte specific 13C labeled metabolome)
In order to determine how the [U-13C6]-fructose tracer-
derived product isotopomers changed with respect to the
different concentrations of fructose, multiple linear
regression analyses were performed to determine the
coefficients of determination (R2) and correlation coeffi-
cients (R). Fructose exposure served as the independent
variable and the 13C-labeled isotopomers were the depen-
dent or response variables. Figure S1 represents the SGBS
isobolome-wide associations in a heat map using the







































































































































































































13C intracellular palmitate in 
differentiating adipocytes
de novo synthesized palmitate in 
differentiating adipocytes 
13C extracellular palmitate in 
differentiating adipocytes
13C intracellular palmitate in 
differentiated adipocytes
de novo synthesized palmitate in 
differentiated adipocytes 
13C extracellular palmitate in 
differentiated adipocytes
Fig. 4 Fructose-induced synthesis and release of palmitate (C16:0) in
adipocytes. Adipocytes were exposed to 0.1, 0.5, 1, 2.5, 5, 7.5 or
10 mM fructose in a medium containing a baseline amount of 5 mM
glucose from the initiation of differentiation for 8 days (differenti-
ating adipocytes) or 16 days (differentiated adipocytes). 10 % of
fructose was supplied as [U-13C6]-fructose for a period of 48 h before
harvest. 13C content (Rmn) of intracellular palmitate in differentiating
(a) and differentiated (b) adipocytes. 13C labeled newly synthesized
intracellular palmitate in differentiating (c) and differentiated (d) adi-
pocytes, 13C content (Rmn) of extracellular palmitate in the medium
form differentiating (e) and differentiated (f) adipocytes
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corresponding fructose concentration. The flux surrogate
markers are positional 13C labeled intermediary metabolic
products that represent specific reactions and their rates in
the isobolome (i.e., the 13C labeled metabolome). The
values are the amount of the fructose-derived metabolites
expressed as percentages of those levels detected in control
adipocytes exposed to 0.1 mM labeled fructose on days 8
or 16, the differentiating (Fig. S1-A) or fully differentiated
adipocytes (Fig. S1-B), respectively. The isotopomer
association patterns for palmitate and oleate showed rela-
tively high R2 and R in differentiating (Fig. S1-A) and
differentiated adipocytes (Fig. S1-B). These results indi-
cated that the palmitate synthesis pathway and extracellular
release of palmitate (limited to differentiated adipocytes)
were strongly associated with the concentration of fructose
in a significant manner and corroborate the lipogenic nature
of fructose. For example, in differentiated adipocytes
(Fig. 6b), the R2 and R values were high and significant for
[13C]-palmitate content (R2 C 0.950 and R C 0.975),
de novo palmitate synthesis via fatty acid synthase
(R2 C 0.974 and R C 0.987), intracellular [13C]-oleate
content (R2 C 0.815 and R C 0.903) and for the palmitate
released (media [13C]-palmitate) 13C content) (R2 C 0.888
and R C 0.943). However, R2 and R values were low and
not significantly correlated for the total cellular palmitate
(peak area) in differentiated adipocytes (R2 = 0.00 and
R = 0.00) (Fig. S1-B) or inversely correlated in differen-
tiating adipocytes (R2 = 0.015 and R = -0.121) (Fig. S1-
A). These results indicated that although palmitate was
robustly labeled and generated from fructose, the fructose-
derived intracellular palmitate is a transient product and is
converted to oleate by elongation or released from the
cells. Hence, the fructose-derived palmitate did not sig-
nificantly alter the overall size of palmitate pool in adi-
pocytes. On comparing the enrichment of palmitate and
oleate (Figs. 5a, b, 6a, b), the enrichment of oleate is higher
than that of palmitate. Oleate accumulation can be seen by
the higher basal levels of labeled oleate compared to that of
labeled palmitate in the control (0.1 mM fructose treated)
adipocytes. Adipocytes store oleate-enriched triglycerides
by elongating unlabeled palmitate into stearate, a process,
as rapid as that of de novo palmitate synthesis. The
increased oleate 13C labeling related to that of palmitate
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differentiating adipocytes
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Fig. 5 Fructose induced oleate (C18:1) synthesis, acetyl-CoA for-
mation and lactate release from adipocytes. Adipocytes were exposed
to 0.1, 0.5, 1, 2.5, 5, 7.5 or 10 mM fructose in a medium containing a
baseline amount of 5 mM glucose from the initiation of differenti-
ation for 8 days (differentiating adipocytes) or 16 days (differentiated
adipocytes). 10 % of fructose was supplied as [U-13C6]-fructose for a
period of 48 h before harvest. Intracellular oleate content in
differentiating (a) and differentiated (b) adipocytes; 13C labeled
intracellular acetyl-CoA in differentiating (c) and differentiated
(d) adipocytes. 13C labeled lactate fraction as percent of total
unlabeled lactate in the media in differentiating (e) adipocytes and in
differentiated adipocytes (f), *p\ 0.05 compared to the 0.1 mM
fructose labeled
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precursor of newly labeled oleate. Since oleic acid gets
readily incorporated into triglycerides as efficiently as its
precursor (palmitate), palmitate’s elongation with fructose-
derived acetyl-CoA into the stored product (oleic acid) is
expected to occur in a lipogenic substrate environment,
such as that observed in this study. However, based on
regression analysis, palmitate enrichment correlated more
strongly with increasing fructose concentrations compared
to that with oleate, in this cell type (Fig. 1a, b)
[(R2 = 0.950 and R = 0.975) for palmitate enrichment in
differentiated adipocytes and (R2 = 0.907 and R = 0.952)
in differentiating adipocytes] and [(R2 = 0.815 and
R = 903) for oleate enrichment in differentiated adipo-
cytes and (R2 = 0.850 and R = 0.922) in differentiating
adipocytes respectively]. These results suggest that that
there is also an attempt by the cell to simultaneously
replenish the palmitate pool in the presence of increasing
fructose concentrations as palmitate formed is being used
up either for conversion to stearate and subsequently oleate
or for release from adipocytes.
In addition to the fatty acid pathways, glutamate syn-
thesis represented by extracellular [13C] media glutamate,
13C glutamate content (R2 = 0.850 and R = 0.922) and
isotopomers of the TCA cycle including PC flux
(R2 = 0.612 and R = -0.782) and PDH flux (R2 = 0.590
and R = 0.768) showed strong and significant correlation
with fructose dose. The correlation between fructose-
derived lactate and the dose of fructose, representing the
lactic acid fermentation pathway, showed statistical sig-
nificance (R2 C 0.886 and R = 0.941) for extracellular
[13C]-lactate content. Similarly, the correlation was sig-
nificant for the association between fructose oxidation to
carbon dioxide and the concentration of fructose
(R2 = 0.296 and R = 0.544) in differentiated adipocytes
(day 16) with a stronger association with fructose































Fig. 6 Schematic of the 13C labeled fructose-derived metabolites in
adipocytes. Adipocytes were exposed to 0.1, 0.5, 1, 2.5, 5, 7.5 or
10 mM fructose in a medium containing a baseline amount of 5 mM
glucose from the initiation of differentiation for 8 days (differenti-
ating adipocytes) or 16 days (differentiated adipocytes). 10 % of
fructose was supplied as [U-13C6]-fructose for a period of 48 h before
harvest. The red arrows indicate the specific fold changes in response
to 5 mM fructose treatment compared to the lowest treatment of
0.1 mM fructose (13CO2, ?1.159; extracellular [
13C]-glutamate,
?7.29; PC flux, -0.32; PDH flux, ?3.979; intracellular [13C]-
palmitate, ?4.89; extracellular release of [13C]-palmitate -1.679;
FAS flux, ?4.339; intracellular [13C]-oleate, ?2.569; extracellular
[13C]-lactate, ?39). G1P glucose 1-phosphate, G6P glucose 6-phos-
phate, G6PDH glucose 6-phosphate dehydrogenase, F6P fructose
6-phosphate, FAS fatty acid synthase, GAP glyceraldehyde 3-phos-
phate, PYR pyruvate, OAA oxaloacetate. : represents increasing fold
change; ; decreasing fold changes and the thickness of the arrow
represents intensity of the fold change
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(day 8). Overall, these results support the conclusion that
fructose was used as a substrate for oxidation in differen-
tiating adipocytes but the primary use of fructose in dif-
ferentiated adipocyte is for anabolic processes such as
synthesis of fatty acids and non-essential amino acids.
Figure 6 is a schematic summarizing the features of
fructose metabolism in adipocytes and the key metabolites
derived from [U-13C6]-fructose in differentiated adipocytes
treated with 5 mM fructose. Most of the labeled fructose
entered the TCA cycle resulting in an increase in glutamate
by 7.2-fold compared to the control. The majority of this
fructose entry into the TCA cycle occurred via a nearly
fourfold increased PDH flux, while the PC flux exhibits a
decrease (-0.32-fold). The increased entry of fructose
through the PDH flux resulted in (i) an increased shuttling
of the fructose-derived acetyl-CoA and citrate into the fatty
acid synthesis pathway, (ii) a 4.33-fold increase in fatty
acid synthase and (iii) a resulting 4.8-fold increase in the
fatty acid palmitate synthesized from fructose. A 2.56-fold
increase was also seen in the formation of oleate. Although
fatty acids, palmitate, and oleate were formed in response
to fructose, only palmitate was released from the cells, a
process augmented by 1.67-fold in presence of 5 mM
fructose.
4 Discussion
A number of potentially deleterious effects have been
attributed to fructose consumption based on reports of the
effects of fructose in rodent and human studies (Aeberli
et al. 2011; Blakely et al. 1981; Elliott et al. 2002; Rizkalla
et al. 1992; Stanhope 2012). These effects include de novo
lipogenesis, hyperlipidemia, hyperuricemia, increased adi-
posity, a decrease in insulin sensitivity, and development of
metabolic syndrome. Many of the effects of fructose can
also result from its metabolism in extra-hepatic tissues.
The intermediary metabolism of fructose in the liver and
hepatocytes is well described and is the subject of many
articles and reviews (Mayes 1993; Tappy and Le 2010;
Tappy et al. 2010). In addition to its effects on the liver,
high fructose feeding in human subjects was also shown to
augment VAT deposition and to increase the waist to hip
ratio in response to fructose- but not glucose-sweetened
beverages or foods (Aeberli et al. 2011). Similar increases
in adiposity were also demonstrated in rodents fed with
dietary fructose (Rizkalla et al. 1992) or fructose contain-
ing beverages (Jurgens et al. 2005). Long-term feeding
studies (up to 6 months) with high fructose corn syrup
showed abnormal weight gain and fat deposition in adipose
tissue and an increase in circulating triglycerides in mice.
The increased adiposity in animals was attributed to
decreased lipolysis and decreased lipid mobilization
(Rizkalla 2010). A few studies examined the metabolism of
fructose in rat adipocytes and adipose tissue (Bellido and
Herrera 1978; Froesch and Ginsberg 1962). However, the
metabolism and the effects of fructose in human adipocytes
had not yet been fully characterized.
The study reported here examined the metabolism of
fructose in human adipocytes using the SIDMAP method
that employed a uniformly labeled [U-13C6]-D-fructose as a
tracer. The targeted tracer fate association method was
used to analyze metabolic fluxes using flux surrogates.
Human adipocytes were exposed to a broad range of
fructose concentrations, based on most common dietary
fructose exposure, to study the metabolic responses of
cultured differentiating and differentiated adipocytes. The
flow of substrate and products through the metabolic net-
work was measured to better understand the metabolic
fates of fructose in adipocytes.
The human SGBS preadipocyte cells (27) were used in
this study owing to their similarities to isolated human
adipocytes. SGBS cells are neither transformed nor
immortalized. These cells can (i) proliferate for up to 50
generations with retained capacity for adipogenic differ-
entiation (38), (ii) efficiently differentiate in the presence
of PPARc agonists, (iii) respond to insulin stimulation by
increasing glucose uptake several fold, (iv) show cate-
cholamine-stimulated lipolysis, and (v) exhibit lipolysis
and apoptosis while expressing/secreting adipokines and
express SLC2A5 the transporter specific for fructose
transport (26). The reported fructose concentrations in
systemic circulation range from 0.05 to 2 mM at basal
levels (Hui et al. 2009; Munstedt et al. 2011; Wahjudi
et al. 2010). Serum fructose concentrations as high as 17
and 10 mM fructose were reported to be measured 30 min
and 2 h, respectively, after a fructose ingestion challenge in
one study (Hui et al. 2009) and 7.2 and 3.6 mM when
measured 1 and 2 h, respectively, in a second study
(Munstedt et al. 2011). These results indicated that fre-
quent consumption of sugar or fructose sweetened bever-
ages and foods can thus maintain high levels of circulating
fructose. Based on these human studies, differentiating and
differentiated adipocytes were exposed to a wide range of
fructose concentrations (0.1–10 mM), and the fructose-
derived metabolic intermediates were examined. The
experimental paradigm consisted of adding the different
concentrations of fructose to a medium containing 5 mM
glucose so as to closely mimic the normal physiological
blood glucose concentrations which is about 5 mM. The
range of fructose concentrations was chosen to cover most
of the reported concentrations of fructose in systemic cir-
culation and to understand the adipocyte metabolic
response to fructose at these levels of exposure.
Carbohydrates are an important source for cellular
energy and are preferentially used over lipids or proteins
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since carbohydrates are not efficiently stored in the body.
The TCA cycle intermediates and products were analyzed
since this is the hub for energy metabolism including the
conversion of pyruvate to acetyl-CoA and subsequently to
CO2, producing energy in the form of ATP (Owen et al.
2002). From the metabolic intermediates evaluated in this
study, fructose was metabolized via glycolysis and the
TCA cycle to produce glutamate, fatty acids, CO2 and
lactate. The responses to fructose were more pronounced in
differentiated adipocytes compared to differentiating adi-
pocytes. Although fructose-derived pyruvate was oxidized
in the TCA cycle in differentiated adipocytes, these cells
did not show a strong dose-dependent increase in CO2
production. However, at the same increasing concentra-
tions of fructose, at which no significant changes in oxi-
dation were observed, fatty acid synthesis occurred
robustly and in a dose dependent manner. In addition,
increasing concentrations of fructose up to 5 mM also
robustly increased [4,5-13C2]-glutamate formation sup-
porting another anabolic role for fructose. Glutamate is
used in biosynthetic pathways leading to the formation of
non-essential amino acids to supply increased protein for
enzyme synthesis (Brosnan 2000). The changes in gluta-
mate production were consistent with the adaptive struc-
tural changes that may occur with the formation of larger
adipocytes with bigger lipid droplets to accommodate the
excess fatty acids in response to fructose. These observa-
tions indicate that anabolic functions such as fatty acid
formation and glutamate synthesis are prominent metabolic
responses to fructose in differentiated adipocytes. Thus,
fructose acts as an anabolic substrate for molecular syn-
thesis and energy storage and much less for oxidation.
In this study, differentiating adipocytes underwent
fructose oxidation along with weaker anabolic responses of
increased total glutamate and palmitate synthesis. The
results presented here indicate that the substrate and energy
requirements in differentiating adipocytes exposed to
fructose differ from those of fully differentiated adipocytes
with cateplerotic process predominating to accommodate
the metabolic changes occurring during the conversion of
preadipocytes to mature adipocytes. Fructose had promi-
nent effects on differentiating and differentiated adipocytes
in this study. Fructose treatment induced adipogenesis in
murine 3T3L1adipocytes (Du and Heaney 2012). While
hypertrophic changes in adipocytes are demonstrated more
conclusively, the occurrence of adipogenesis in adult adi-
pose tissue is not fully established (Cristancho and Lazar
2011). In humans, adipose tissue is reported to undergo a
10 % annual turnover suggesting that adipogenesis occurs
although at a small rate in adults, maintaining the adipose
depot (Spalding et al. 2008). In vivo rodent studies have
demonstrated an increase in cell numbers reflecting adi-
pogenesis along with hypertrophic changes in cell size in
response to over nutrition (Klyde and Hirsch 1979). Similar
results have been observed in short term feeding studies in
humans (Tchoukalova et al. 2010). The differences
between differentiating and differentiated adipocytes in our
studies suggest that the fructose overfeeding would lead to
hypertrophic changes as a more prominent response. Lar-
ger adipocytes seen in obesity demonstrate higher and
altered capacity in triglyceride accumulation and fatty acid
efflux (Bjorntorp and Karlsson 1970).
When adipocytes were exposed to increasing concen-
trations of fructose, the PDH flux increased which resulted
in increased pyruvate/citrate cycling in the TCA cycle. A
primary product resulting from the increased PDH flux was
citrate, which in excess was shuttled towards the fatty acid
synthesis pathway. These results elucidate the lipogenic
potential of fructose in adipocytes. Fructose-induced lipo-
genesis has been reported in liver and hepatocytes (Samuel
2011) and activation of PDH has been shown to be key
regulatory step in this process in hepatocytes (Da Silva
et al. 1992). Simultaneously, with the augmented PDH flux
in adipocytes in this study, a dose dependent decrease was
seen in the PC flux. A dose-dependent increase in released
lactate was seen in the presence of high concentrations of
fructose. These high fructose concentrations also were
associated with increased FA synthesis. Others have shown
that lactate was a significant precursor for triacylglycerol
synthesis in adipocytes (Francendese and Digirolamo
1981). This study demonstrated that in adipocytes provided
with excess fructose, palmitate was the primary fatty acid
synthesized robustly by de novo fatty acid synthesis med-
iated by fatty acid synthase. In addition to palmitate,
fructose also increased the formation of oleate resulting
from the action of fatty acid elongase and desaturase that
convert palmitate to oleate. An unsaturated fatty acid such
as oleate is a preferred storage form of fatty acid in cells
(Gavino and Gavino 1992; Kokatnur et al. 1992). Hence,
fructose promotes the storage of fatty acids in adipocytes
similar to that seen in hepatocytes.
In addition to augmenting the storage of fatty acids in
adipocytes, fructose also enhances the release of FFA from
adipocytes. Adipocytes release FFA by hydrolytic cleavage
of triacylglycerols by the adipocyte specific hormone sen-
sitive lipase or by the triacylglycerol hydrolase, Adipose
triglyceride lipase, generating non-esterified fatty acids
(Lass et al. 2011; Wang et al. 2008). In this study, the
fructose-treated differentiated adipocytes dose-dependently
increased the release of palmitate. However, fructose did
not stimulate the release of oleate in adipocytes while it
increased its formation suggesting that oleate is preferen-
tially stored in adipocytes.
Adipocytes are localized in separate depots of adipose
tissue most prominently in the VAT found in the intra-
abdominal region and the subcutaneous adipose tissue
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(SAT) found peripherally (Lee, et al. 2013). Adipocytes
are exposed to fructose via peripheral systemic circulation
in the case of SAT or via the celiac or mesenteric arteries
that supply the splanchnic/mesenteric bed associated with
VAT. These arteries supply the intra-abdominal tissues,
including intestinal tissue where fructose is absorbed, and
anastomose extensively prior to emptying into portal vein
(Andrew et al. 2005; Jacobson 1982; Parks and Jacobson
1985). The result of these anatomical and physiological
processes is that VAT may be exposed to high concentra-
tions of metabolites including fructose absorbed by the
intestines prior to entering the portal vein that supplies the
liver. Although the adipocytes used in this study are
derived originally from SAT a similar response to fructose
exposure by VAT may affect the liver due to the direct
access via the portal vein, and hence would have systemic
implications. While both SAT and VAT are associated with
the development of metabolic syndrome, VAT is more
strongly associated with the increased risk of developing
hepatic insulin resistance and metabolic syndrome, while
SAT can contribute to peripheral insulin resistance (Jensen
2008; Klein 2004). Increased FFA release from SAT can
accumulate as intramyocellular lipids in ectopic tissues
such as skeletal muscle leading to peripheral insulin
resistance (Koutsari and Jensen 2006). Additionally, fruc-
tose-induced release of FFAs can cause lipotoxicity in the
liver and pancreas. Non-alcoholic fatty liver disease, which
can result from lipotoxicity of the liver, has also been
shown to be associated with cardiovascular conditions such
as cardiac lipotoxicity, ischemia, and diastolic dysfunction
of the heart (Cusi 2012).
Taken together, the results presented here revealed that
fructose can significantly augment the accumulation of
fatty acids palmitate and oleate in differentiated adipocytes
and simultaneously increase the release of palmitate from
adipocytes. Fructose was not an efficient substrate for
oxidation but was an anabolic substrate for glutamate and
fatty acid synthesis. Conversion to lactate occurred only at
very high fructose concentrations in this model. Thus, the
formation and accumulation of fatty acids is one of the key
consequences of fructose metabolism in adipocytes. Fruc-
tose-induced increase in adiposity can further trigger adi-
pocyte dysfunction leading to altered secretion of fatty
acids and adipokines and an increase in ER stress and
inflammation (de Ferranti and Mozaffarian 2008) which
can further accelerate the development of insulin resistance
in addition to the lipotoxic effects of fructose.
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